Biomagnetics Diagnostics receives commitment for clinical validation testing in India for malaria, TB diagnosis

Biomagnetics Diagnostics Corp., (PINK SHEETS:BMGP) a developer of revolutionary diagnostic systems and technology for HIV, hepatitis, tuberculosis and malaria detection, today announced it has received important commitments from two leading research laboratories in India for clinical validation testing for malaria and tuberculosis (TB) detection and diagnosis.

“Patent License Agreement with Los Alamos National Security.”

During a recent trip to India, Company personnel secured a commitment from the National Institute of Malaria Research, an autonomous department of the Health Ministry of India for validation of the Company's malaria test assay to be used in conjunction with the Company's Integrated Optical Biosensor (IOBS) platform that will be launched later this year. Additionally, Biomagnetics Diagnostics, Corp. has also received a commitment from the National Hospital & Medical Research Center, a nonprofit foundation for the Hinduja Group of Mumbai, India. The research center has agreed to perform validation testing of the IBOS platform for human tuberculosis diagnosis.

Successful completion of this validation testing will allow Biomagnetics Diagnostics to market this revolutionary, low-cost handheld diagnostic tool throughout India without additional clinical testing being required for both malaria and tuberculosis detection and diagnosis.

"We are very excited about these developments as the National Institute of Malaria Research in India is on the forefront of diagnostic research within this field of study. Additionally, the Hinduja Group is a leader in the field of tuberculosis research. Completion of the testing will not only allow us to sell the product throughout India, but will also lend additional credibility to our overall story enabling us to accelerate sales relating to malaria diagnostics in other countries, commented, Clayton Hardman, CEO of Biomagnetics Diagnostics, Corp. "We believe the validation testing will be an important step to the overall commercialization of this life-saving technology and will allow us to forgo additional validation testing in many countries around the world."

The Company recently announced it had finalized a "Patent License Agreement with Los Alamos National Security." Under the agreement, Biomagnetics will have access to the Triggered Optical Biosensor and Integrated Optical Biosensor System (IBOS) technology developed at Los Alamos National Laboratory. Biomagnetics Diagnostics believes the availability of this portable, handheld technology will substantially lower the cost of, and substantially raise the availability of, malaria, tuberculosis, HIV/AIDS and cholera diagnosis and detection in many areas throughout the world, potentially saving hundreds of thousands of lives each year.

Source Biomagnetics Diagnostics Corp.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
UNICEF delivers first R21/Matrix-M malaria vaccine doses to Central African Republic